img

Global Anti-Obesity Prescription Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-Obesity Prescription Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory failure, renal failure and asthma. According to a World Health Organization (WHO) report published in 2014, around 3.4 million adults in the world die each year due to obesity related issues. Increasing prevalence of obesity among children and adults is posing a threat and developing nations. Effective intervention strategies such as increased physical activity, behavioral and dietary changes are commonly used to control and prevent obesity. Obesity has a major impact on population longevity and health related expense.
The global Anti-Obesity Prescription market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
There is increased use of anti-obesity prescription due to increasing obesity endemic. Sedentary lifestyle and junk food habits, increasing healthcare expenditure and rise in aging population are some of the key factors driving the growth for global anti-obesity prescription market. In addition, increasing healthcare awareness is also fuelling the growth of the global anti-obesity prescription market. However, side effects of anti-obesity drugs, high drug development cost and strict regulatory framework are some of the major factors restraining the growth for the global anti-obesity prescription market.
In terms of sales (consumption) side, this report focuses on the sales of Anti-Obesity Prescription by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Anti-Obesity Prescription market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Anti-Obesity Prescription market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Zydus Cadila
Akrimax Pharmaceuticals
Zealand Pharma
Arrowhead Research
Arena Pharmaceuticals
Compellis Pharmaceuticals
Yungjin Pharm
Alpex Pharma
Bridge BioResearch
By Type
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
By Application
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Anti-Obesity Prescription in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Anti-Obesity Prescription manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Obesity Prescription sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Anti-Obesity Prescription Definition
1.2 Market by Type
1.2.1 Global Anti-Obesity Prescription Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Bupropion and Naltrexone
1.2.3 Orlistat
1.2.4 Lorcaserin
1.2.5 Phentermine and Topiramate
1.2.6 Liraglutide
1.3 Market Segment by Application
1.3.1 Global Anti-Obesity Prescription Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 E-Commerce
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Anti-Obesity Prescription Sales
2.1 Global Anti-Obesity Prescription Revenue Estimates and Forecasts 2018-2034
2.2 Global Anti-Obesity Prescription Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Anti-Obesity Prescription Revenue by Region
2.3.1 Global Anti-Obesity Prescription Revenue by Region (2018-2023)
2.3.2 Global Anti-Obesity Prescription Revenue by Region (2024-2034)
2.4 Global Anti-Obesity Prescription Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Anti-Obesity Prescription Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Anti-Obesity Prescription Sales Quantity by Region
2.6.1 Global Anti-Obesity Prescription Sales Quantity by Region (2018-2023)
2.6.2 Global Anti-Obesity Prescription Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Anti-Obesity Prescription Sales Quantity by Manufacturers
3.1.1 Global Anti-Obesity Prescription Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Anti-Obesity Prescription Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Anti-Obesity Prescription Sales in 2024
3.2 Global Anti-Obesity Prescription Revenue by Manufacturers
3.2.1 Global Anti-Obesity Prescription Revenue by Manufacturers (2018-2023)
3.2.2 Global Anti-Obesity Prescription Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Anti-Obesity Prescription Revenue in 2024
3.3 Global Anti-Obesity Prescription Sales Price by Manufacturers
3.4 Global Key Players of Anti-Obesity Prescription, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-Obesity Prescription Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-Obesity Prescription, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-Obesity Prescription, Product Offered and Application
3.8 Global Key Manufacturers of Anti-Obesity Prescription, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Anti-Obesity Prescription Sales Quantity by Type
4.1.1 Global Anti-Obesity Prescription Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Anti-Obesity Prescription Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Anti-Obesity Prescription Sales Quantity Market Share by Type (2018-2034)
4.2 Global Anti-Obesity Prescription Revenue by Type
4.2.1 Global Anti-Obesity Prescription Historical Revenue by Type (2018-2023)
4.2.2 Global Anti-Obesity Prescription Forecasted Revenue by Type (2024-2034)
4.2.3 Global Anti-Obesity Prescription Revenue Market Share by Type (2018-2034)
4.3 Global Anti-Obesity Prescription Price by Type
4.3.1 Global Anti-Obesity Prescription Price by Type (2018-2023)
4.3.2 Global Anti-Obesity Prescription Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Anti-Obesity Prescription Sales Quantity by Application
5.1.1 Global Anti-Obesity Prescription Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Anti-Obesity Prescription Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Anti-Obesity Prescription Sales Quantity Market Share by Application (2018-2034)
5.2 Global Anti-Obesity Prescription Revenue by Application
5.2.1 Global Anti-Obesity Prescription Historical Revenue by Application (2018-2023)
5.2.2 Global Anti-Obesity Prescription Forecasted Revenue by Application (2024-2034)
5.2.3 Global Anti-Obesity Prescription Revenue Market Share by Application (2018-2034)
5.3 Global Anti-Obesity Prescription Price by Application
5.3.1 Global Anti-Obesity Prescription Price by Application (2018-2023)
5.3.2 Global Anti-Obesity Prescription Price Forecast by Application (2024-2034)
6 North America
6.1 North America Anti-Obesity Prescription Sales by Company
6.1.1 North America Anti-Obesity Prescription Revenue by Company (2018-2023)
6.1.2 North America Anti-Obesity Prescription Sales Quantity by Company (2018-2023)
6.2 North America Anti-Obesity Prescription Market Size by Type
6.2.1 North America Anti-Obesity Prescription Sales Quantity by Type (2018-2034)
6.2.2 North America Anti-Obesity Prescription Revenue by Type (2018-2034)
6.3 North America Anti-Obesity Prescription Market Size by Application
6.3.1 North America Anti-Obesity Prescription Sales Quantity by Application (2018-2034)
6.3.2 North America Anti-Obesity Prescription Revenue by Application (2018-2034)
6.4 North America Anti-Obesity Prescription Market Size by Country
6.4.1 North America Anti-Obesity Prescription Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Anti-Obesity Prescription Revenue by Country (2018-2034)
6.4.3 North America Anti-Obesity Prescription Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Anti-Obesity Prescription Sales by Company
7.1.1 Europe Anti-Obesity Prescription Sales Quantity by Company (2018-2023)
7.1.2 Europe Anti-Obesity Prescription Revenue by Company (2018-2023)
7.2 Europe Anti-Obesity Prescription Market Size by Type
7.2.1 Europe Anti-Obesity Prescription Sales Quantity by Type (2018-2034)
7.2.2 Europe Anti-Obesity Prescription Revenue by Type (2018-2034)
7.3 Europe Anti-Obesity Prescription Market Size by Application
7.3.1 Europe Anti-Obesity Prescription Sales Quantity by Application (2018-2034)
7.3.2 Europe Anti-Obesity Prescription Revenue by Application (2018-2034)
7.4 Europe Anti-Obesity Prescription Market Size by Country
7.4.1 Europe Anti-Obesity Prescription Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Anti-Obesity Prescription Revenue by Country (2018-2034)
7.4.3 Europe Anti-Obesity Prescription Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Anti-Obesity Prescription Sales by Company
8.1.1 China Anti-Obesity Prescription Sales Quantity by Company (2018-2023)
8.1.2 China Anti-Obesity Prescription Revenue by Company (2018-2023)
8.2 China Anti-Obesity Prescription Market Size by Type
8.2.1 China Anti-Obesity Prescription Sales Quantity by Type (2018-2034)
8.2.2 China Anti-Obesity Prescription Revenue by Type (2018-2034)
8.3 China Anti-Obesity Prescription Market Size by Application
8.3.1 China Anti-Obesity Prescription Sales Quantity by Application (2018-2034)
8.3.2 China Anti-Obesity Prescription Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Anti-Obesity Prescription Sales by Company
9.1.1 APAC Anti-Obesity Prescription Sales Quantity by Company (2018-2023)
9.1.2 APAC Anti-Obesity Prescription Revenue by Company (2018-2023)
9.2 APAC Anti-Obesity Prescription Market Size by Type
9.2.1 APAC Anti-Obesity Prescription Sales Quantity by Type (2018-2034)
9.2.2 APAC Anti-Obesity Prescription Revenue by Type (2018-2034)
9.3 APAC Anti-Obesity Prescription Market Size by Application
9.3.1 APAC Anti-Obesity Prescription Sales Quantity by Application (2018-2034)
9.3.2 APAC Anti-Obesity Prescription Revenue by Application (2018-2034)
9.4 APAC Anti-Obesity Prescription Market Size by Region
9.4.1 APAC Anti-Obesity Prescription Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Anti-Obesity Prescription Revenue by Region (2018-2034)
9.4.3 APAC Anti-Obesity Prescription Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-Obesity Prescription Sales by Company
10.1.1 Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Anti-Obesity Prescription Market Size by Type
10.2.1 Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Anti-Obesity Prescription Market Size by Application
10.3.1 Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Anti-Obesity Prescription Market Size by Country
10.4.1 Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Zydus Cadila
11.1.1 Zydus Cadila Company Information
11.1.2 Zydus Cadila Overview
11.1.3 Zydus Cadila Anti-Obesity Prescription Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Zydus Cadila Anti-Obesity Prescription Products and Services
11.1.5 Zydus Cadila Anti-Obesity Prescription SWOT Analysis
11.1.6 Zydus Cadila Recent Developments
11.2 Akrimax Pharmaceuticals
11.2.1 Akrimax Pharmaceuticals Company Information
11.2.2 Akrimax Pharmaceuticals Overview
11.2.3 Akrimax Pharmaceuticals Anti-Obesity Prescription Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Akrimax Pharmaceuticals Anti-Obesity Prescription Products and Services
11.2.5 Akrimax Pharmaceuticals Anti-Obesity Prescription SWOT Analysis
11.2.6 Akrimax Pharmaceuticals Recent Developments
11.3 Zealand Pharma
11.3.1 Zealand Pharma Company Information
11.3.2 Zealand Pharma Overview
11.3.3 Zealand Pharma Anti-Obesity Prescription Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Zealand Pharma Anti-Obesity Prescription Products and Services
11.3.5 Zealand Pharma Anti-Obesity Prescription SWOT Analysis
11.3.6 Zealand Pharma Recent Developments
11.4 Arrowhead Research
11.4.1 Arrowhead Research Company Information
11.4.2 Arrowhead Research Overview
11.4.3 Arrowhead Research Anti-Obesity Prescription Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Arrowhead Research Anti-Obesity Prescription Products and Services
11.4.5 Arrowhead Research Anti-Obesity Prescription SWOT Analysis
11.4.6 Arrowhead Research Recent Developments
11.5 Arena Pharmaceuticals
11.5.1 Arena Pharmaceuticals Company Information
11.5.2 Arena Pharmaceuticals Overview
11.5.3 Arena Pharmaceuticals Anti-Obesity Prescription Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Arena Pharmaceuticals Anti-Obesity Prescription Products and Services
11.5.5 Arena Pharmaceuticals Anti-Obesity Prescription SWOT Analysis
11.5.6 Arena Pharmaceuticals Recent Developments
11.6 Compellis Pharmaceuticals
11.6.1 Compellis Pharmaceuticals Company Information
11.6.2 Compellis Pharmaceuticals Overview
11.6.3 Compellis Pharmaceuticals Anti-Obesity Prescription Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Compellis Pharmaceuticals Anti-Obesity Prescription Products and Services
11.6.5 Compellis Pharmaceuticals Anti-Obesity Prescription SWOT Analysis
11.6.6 Compellis Pharmaceuticals Recent Developments
11.7 Yungjin Pharm
11.7.1 Yungjin Pharm Company Information
11.7.2 Yungjin Pharm Overview
11.7.3 Yungjin Pharm Anti-Obesity Prescription Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Yungjin Pharm Anti-Obesity Prescription Products and Services
11.7.5 Yungjin Pharm Anti-Obesity Prescription SWOT Analysis
11.7.6 Yungjin Pharm Recent Developments
11.8 Alpex Pharma
11.8.1 Alpex Pharma Company Information
11.8.2 Alpex Pharma Overview
11.8.3 Alpex Pharma Anti-Obesity Prescription Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Alpex Pharma Anti-Obesity Prescription Products and Services
11.8.5 Alpex Pharma Anti-Obesity Prescription SWOT Analysis
11.8.6 Alpex Pharma Recent Developments
11.9 Bridge BioResearch
11.9.1 Bridge BioResearch Company Information
11.9.2 Bridge BioResearch Overview
11.9.3 Bridge BioResearch Anti-Obesity Prescription Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Bridge BioResearch Anti-Obesity Prescription Products and Services
11.9.5 Bridge BioResearch Anti-Obesity Prescription SWOT Analysis
11.9.6 Bridge BioResearch Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Anti-Obesity Prescription Value Chain Analysis
12.2 Anti-Obesity Prescription Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-Obesity Prescription Production Mode & Process
12.4 Anti-Obesity Prescription Sales and Marketing
12.4.1 Anti-Obesity Prescription Sales Channels
12.4.2 Anti-Obesity Prescription Distributors
12.5 Anti-Obesity Prescription Customers
13 Market Dynamics
13.1 Anti-Obesity Prescription Industry Trends
13.2 Anti-Obesity Prescription Market Drivers
13.3 Anti-Obesity Prescription Market Challenges
13.4 Anti-Obesity Prescription Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-Obesity Prescription Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Bupropion and Naltrexone
Table 3. Major Manufacturers of Orlistat
Table 4. Major Manufacturers of Lorcaserin
Table 5. Major Manufacturers of Phentermine and Topiramate
Table 6. Major Manufacturers of Liraglutide
Table 7. Global Anti-Obesity Prescription Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Anti-Obesity Prescription Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Anti-Obesity Prescription Revenue by Region (2018-2023) & (US$ Million)
Table 10. Global Anti-Obesity Prescription Revenue Market Share by Region (2018-2023)
Table 11. Global Anti-Obesity Prescription Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Anti-Obesity Prescription Revenue Market Share by Region (2024-2034)
Table 13. Global Anti-Obesity Prescription Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 14. Global Anti-Obesity Prescription Sales by Region (2018-2023) & (K Units)
Table 15. Global Anti-Obesity Prescription Sales Market Share by Region (2018-2023)
Table 16. Global Anti-Obesity Prescription Sales by Region (2024-2034) & (K Units)
Table 17. Global Anti-Obesity Prescription Sales Market Share by Region (2024-2034)
Table 18. Global Anti-Obesity Prescription Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 19. Global Anti-Obesity Prescription Sales Quantity Share by Manufacturers (2018-2023)
Table 20. Global Anti-Obesity Prescription Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 21. Global Anti-Obesity Prescription Revenue Share by Manufacturers (2018-2023)
Table 22. Global Anti-Obesity Prescription Price by Manufacturers 2018-2023 (USD/Unit)
Table 23. Global Key Players of Anti-Obesity Prescription, Industry Ranking, 2021 VS 2024
Table 24. Global Anti-Obesity Prescription Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Anti-Obesity Prescription by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Obesity Prescription as of 2024)
Table 26. Global Key Manufacturers of Anti-Obesity Prescription, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Anti-Obesity Prescription, Product Offered and Application
Table 28. Global Key Manufacturers of Anti-Obesity Prescription, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Anti-Obesity Prescription Sales Quantity by Type (2018-2023) & (K Units)
Table 31. Global Anti-Obesity Prescription Sales Quantity by Type (2024-2034) & (K Units)
Table 32. Global Anti-Obesity Prescription Sales Quantity Share by Type (2018-2023)
Table 33. Global Anti-Obesity Prescription Sales Quantity Share by Type (2024-2034)
Table 34. Global Anti-Obesity Prescription Revenue by Type (2018-2023) & (US$ Million)
Table 35. Global Anti-Obesity Prescription Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Anti-Obesity Prescription Revenue Share by Type (2018-2023)
Table 37. Global Anti-Obesity Prescription Revenue Share by Type (2024-2034)
Table 38. Anti-Obesity Prescription Price by Type (2018-2023) & (USD/Unit)
Table 39. Global Anti-Obesity Prescription Price Forecast by Type (2024-2034) & (USD/Unit)
Table 40. Global Anti-Obesity Prescription Sales Quantity by Application (2018-2023) & (K Units)
Table 41. Global Anti-Obesity Prescription Sales Quantity by Application (2024-2034) & (K Units)
Table 42. Global Anti-Obesity Prescription Sales Quantity Share by Application (2018-2023)
Table 43. Global Anti-Obesity Prescription Sales Quantity Share by Application (2024-2034)
Table 44. Global Anti-Obesity Prescription Revenue by Application (2018-2023) & (US$ Million)
Table 45. Global Anti-Obesity Prescription Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Anti-Obesity Prescription Revenue Share by Application (2018-2023)
Table 47. Global Anti-Obesity Prescription Revenue Share by Application (2024-2034)
Table 48. Anti-Obesity Prescription Price by Application (2018-2023) & (USD/Unit)
Table 49. Global Anti-Obesity Prescription Price Forecast by Application (2024-2034) & (USD/Unit)
Table 50. North America Anti-Obesity Prescription Revenue by Company (2018-2023) & (US$ Million)
Table 51. North America Anti-Obesity Prescription Sales Quantity by Company (2018-2023) & (K Units)
Table 52. North America Anti-Obesity Prescription Sales Quantity by Type (2018-2023) & (K Units)
Table 53. North America Anti-Obesity Prescription Sales Quantity by Type (2024-2034) & (K Units)
Table 54. North America Anti-Obesity Prescription Revenue by Type (2018-2023) & (US$ Million)
Table 55. North America Anti-Obesity Prescription Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Anti-Obesity Prescription Sales Quantity by Application (2018-2023) & (K Units)
Table 57. North America Anti-Obesity Prescription Sales Quantity by Application (2024-2034) & (K Units)
Table 58. North America Anti-Obesity Prescription Revenue by Application (2018-2023) & (US$ Million)
Table 59. North America Anti-Obesity Prescription Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Anti-Obesity Prescription Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 61. North America Anti-Obesity Prescription Revenue by Country (2018-2023) & (US$ Million)
Table 62. North America Anti-Obesity Prescription Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Anti-Obesity Prescription Sales Quantity by Country (2018-2023) & (K Units)
Table 64. North America Anti-Obesity Prescription Sales Quantity by Country (2024-2034) & (K Units)
Table 65. Europe Anti-Obesity Prescription Sales Quantity by Company (2018-2023) & (K Units)
Table 66. Europe Anti-Obesity Prescription Revenue by Company (2018-2023) & (US$ Million)
Table 67. Europe Anti-Obesity Prescription Sales Quantity by Type (2018-2023) & (K Units)
Table 68. Europe Anti-Obesity Prescription Sales Quantity by Type (2024-2034) & (K Units)
Table 69. Europe Anti-Obesity Prescription Revenue by Type (2018-2023) & (US$ Million)
Table 70. Europe Anti-Obesity Prescription Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Anti-Obesity Prescription Sales Quantity by Application (2018-2023) & (K Units)
Table 72. Europe Anti-Obesity Prescription Sales Quantity by Application (2024-2034) & (K Units)
Table 73. Europe Anti-Obesity Prescription Revenue by Application (2018-2023) & (US$ Million)
Table 74. Europe Anti-Obesity Prescription Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Anti-Obesity Prescription Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 76. Europe Anti-Obesity Prescription Revenue by Country (2018-2023) & (US$ Million)
Table 77. Europe Anti-Obesity Prescription Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Anti-Obesity Prescription Sales Quantity by Country (2018-2023) & (K Units)
Table 79. Europe Anti-Obesity Prescription Sales Quantity by Country (2024-2034) & (K Units)
Table 80. China Anti-Obesity Prescription Sales Quantity by Company (2018-2023) & (K Units)
Table 81. China Anti-Obesity Prescription Revenue by Company (2018-2023) & (US$ Million)
Table 82. China Anti-Obesity Prescription Sales Quantity by Type (2018-2023) & (K Units)
Table 83. China Anti-Obesity Prescription Sales Quantity by Type (2024-2034) & (K Units)
Table 84. China Anti-Obesity Prescription Revenue by Type (2018-2023) & (US$ Million)
Table 85. China Anti-Obesity Prescription Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Anti-Obesity Prescription Sales Quantity by Application (2018-2023) & (K Units)
Table 87. China Anti-Obesity Prescription Sales Quantity by Application (2024-2034) & (K Units)
Table 88. China Anti-Obesity Prescription Revenue by Application (2018-2023) & (US$ Million)
Table 89. China Anti-Obesity Prescription Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Anti-Obesity Prescription Sales Quantity by Company (2018-2023) & (K Units)
Table 91. APAC Anti-Obesity Prescription Revenue by Company (2018-2023) & (US$ Million)
Table 92. APAC Anti-Obesity Prescription Sales Quantity by Type (2018-2023) & (K Units)
Table 93. APAC Anti-Obesity Prescription Sales Quantity by Type (2024-2034) & (K Units)
Table 94. APAC Anti-Obesity Prescription Revenue by Type (2018-2023) & (US$ Million)
Table 95. APAC Anti-Obesity Prescription Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Anti-Obesity Prescription Sales Quantity by Application (2018-2023) & (K Units)
Table 97. APAC Anti-Obesity Prescription Sales Quantity by Application (2024-2034) & (K Units)
Table 98. APAC Anti-Obesity Prescription Revenue by Application (2018-2023) & (US$ Million)
Table 99. APAC Anti-Obesity Prescription Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Anti-Obesity Prescription Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 101. APAC Anti-Obesity Prescription Revenue by Region (2018-2023) & (US$ Million)
Table 102. APAC Anti-Obesity Prescription Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Anti-Obesity Prescription Sales Quantity by Region (2018-2023) & (K Units)
Table 104. APAC Anti-Obesity Prescription Sales Quantity by Region (2024-2034) & (K Units)
Table 105. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Company (2018-2023) & (K Units)
Table 106. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Company (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Type (2018-2023) & (K Units)
Table 108. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Type (2024-2034) & (K Units)
Table 109. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Type (2018-2023) & (US$ Million)
Table 110. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Application (2018-2023) & (K Units)
Table 112. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Application (2024-2034) & (K Units)
Table 113. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Application (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Country (2018-2023) & (US$ Million)
Table 117. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Country (2018-2023) & (K Units)
Table 119. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity by Country (2024-2034) & (K Units)
Table 120. Zydus Cadila Company Information
Table 121. Zydus Cadila Description and Overview
Table 122. Zydus Cadila Anti-Obesity Prescription Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 123. Zydus Cadila Anti-Obesity Prescription Product and Services
Table 124. Zydus Cadila Anti-Obesity Prescription SWOT Analysis
Table 125. Zydus Cadila Recent Developments
Table 126. Akrimax Pharmaceuticals Company Information
Table 127. Akrimax Pharmaceuticals Description and Overview
Table 128. Akrimax Pharmaceuticals Anti-Obesity Prescription Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 129. Akrimax Pharmaceuticals Anti-Obesity Prescription Product and Services
Table 130. Akrimax Pharmaceuticals Anti-Obesity Prescription SWOT Analysis
Table 131. Akrimax Pharmaceuticals Recent Developments
Table 132. Zealand Pharma Company Information
Table 133. Zealand Pharma Description and Overview
Table 134. Zealand Pharma Anti-Obesity Prescription Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 135. Zealand Pharma Anti-Obesity Prescription Product and Services
Table 136. Zealand Pharma Anti-Obesity Prescription SWOT Analysis
Table 137. Zealand Pharma Recent Developments
Table 138. Arrowhead Research Company Information
Table 139. Arrowhead Research Description and Overview
Table 140. Arrowhead Research Anti-Obesity Prescription Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 141. Arrowhead Research Anti-Obesity Prescription Product and Services
Table 142. Arrowhead Research Anti-Obesity Prescription SWOT Analysis
Table 143. Arrowhead Research Recent Developments
Table 144. Arena Pharmaceuticals Company Information
Table 145. Arena Pharmaceuticals Description and Overview
Table 146. Arena Pharmaceuticals Anti-Obesity Prescription Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 147. Arena Pharmaceuticals Anti-Obesity Prescription Product and Services
Table 148. Arena Pharmaceuticals Anti-Obesity Prescription SWOT Analysis
Table 149. Arena Pharmaceuticals Recent Developments
Table 150. Compellis Pharmaceuticals Company Information
Table 151. Compellis Pharmaceuticals Description and Overview
Table 152. Compellis Pharmaceuticals Anti-Obesity Prescription Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 153. Compellis Pharmaceuticals Anti-Obesity Prescription Product and Services
Table 154. Compellis Pharmaceuticals Anti-Obesity Prescription SWOT Analysis
Table 155. Compellis Pharmaceuticals Recent Developments
Table 156. Yungjin Pharm Company Information
Table 157. Yungjin Pharm Description and Overview
Table 158. Yungjin Pharm Anti-Obesity Prescription Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 159. Yungjin Pharm Anti-Obesity Prescription Product and Services
Table 160. Yungjin Pharm Anti-Obesity Prescription SWOT Analysis
Table 161. Yungjin Pharm Recent Developments
Table 162. Alpex Pharma Company Information
Table 163. Alpex Pharma Description and Overview
Table 164. Alpex Pharma Anti-Obesity Prescription Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 165. Alpex Pharma Anti-Obesity Prescription Product and Services
Table 166. Alpex Pharma Anti-Obesity Prescription SWOT Analysis
Table 167. Alpex Pharma Recent Developments
Table 168. Bridge BioResearch Company Information
Table 169. Bridge BioResearch Description and Overview
Table 170. Bridge BioResearch Anti-Obesity Prescription Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 171. Bridge BioResearch Anti-Obesity Prescription Product and Services
Table 172. Bridge BioResearch Anti-Obesity Prescription SWOT Analysis
Table 173. Bridge BioResearch Recent Developments
Table 174. Key Raw Materials Lists
Table 175. Raw Materials Key Suppliers Lists
Table 176. Anti-Obesity Prescription Distributors List
Table 177. Anti-Obesity Prescription Customers List
Table 178. Anti-Obesity Prescription Market Trends
Table 179. Anti-Obesity Prescription Market Drivers
Table 180. Anti-Obesity Prescription Market Challenges
Table 181. Anti-Obesity Prescription Market Restraints
Table 182. Research Programs/Design for This Report
Table 183. Key Data Information from Secondary Sources
Table 184. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Obesity Prescription Product Picture
Figure 2. Global Anti-Obesity Prescription Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Anti-Obesity Prescription Market Share by Type in 2024 & 2034
Figure 4. Bupropion and Naltrexone Product Picture
Figure 5. Orlistat Product Picture
Figure 6. Lorcaserin Product Picture
Figure 7. Phentermine and Topiramate Product Picture
Figure 8. Liraglutide Product Picture
Figure 9. Global Anti-Obesity Prescription Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 10. Global Anti-Obesity Prescription Market Share by Application in 2024 & 2034
Figure 11. Hospital Pharmacies
Figure 12. Retail Pharmacies
Figure 13. E-Commerce
Figure 14. Anti-Obesity Prescription Report Years Considered
Figure 15. Global Anti-Obesity Prescription Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 16. Global Anti-Obesity Prescription Revenue 2018-2034 (US$ Million)
Figure 17. Global Anti-Obesity Prescription Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 18. Global Anti-Obesity Prescription Sales Quantity 2018-2034 (K Units)
Figure 19. Global Anti-Obesity Prescription Sales Quantity Market Share by Region (2018-2023)
Figure 20. Global Anti-Obesity Prescription Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America Anti-Obesity Prescription Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. North America Anti-Obesity Prescription Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Anti-Obesity Prescription Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. Europe Anti-Obesity Prescription Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Anti-Obesity Prescription Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. China Anti-Obesity Prescription Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC Anti-Obesity Prescription Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. APAC Anti-Obesity Prescription Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity YoY (2018-2034) & (K Units)
Figure 30. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by Anti-Obesity Prescription Sales Quantity in 2024
Figure 32. The Top 10 and Top 5 Players Market Share by Anti-Obesity Prescription Revenue in 2024
Figure 33. Anti-Obesity Prescription Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 34. Global Anti-Obesity Prescription Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global Anti-Obesity Prescription Revenue Market Share by Type (2018-2034)
Figure 36. Global Anti-Obesity Prescription Sales Quantity Market Share by Application (2018-2034)
Figure 37. Global Anti-Obesity Prescription Revenue Market Share by Application (2018-2034)
Figure 38. North America Anti-Obesity Prescription Revenue Market Share by Company in 2024
Figure 39. North America Anti-Obesity Prescription Sales Quantity Market Share by Company in 2024
Figure 40. North America Anti-Obesity Prescription Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America Anti-Obesity Prescription Revenue Market Share by Type (2018-2034)
Figure 42. North America Anti-Obesity Prescription Sales Quantity Market Share by Application (2018-2034)
Figure 43. North America Anti-Obesity Prescription Revenue Market Share by Application (2018-2034)
Figure 44. North America Anti-Obesity Prescription Revenue Share by Country (2018-2034)
Figure 45. North America Anti-Obesity Prescription Sales Quantity Share by Country (2018-2034)
Figure 46. U.S. Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 47. Canada Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 48. Europe Anti-Obesity Prescription Sales Quantity Market Share by Company in 2024
Figure 49. Europe Anti-Obesity Prescription Revenue Market Share by Company in 2024
Figure 50. Europe Anti-Obesity Prescription Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe Anti-Obesity Prescription Revenue Market Share by Type (2018-2034)
Figure 52. Europe Anti-Obesity Prescription Sales Quantity Market Share by Application (2018-2034)
Figure 53. Europe Anti-Obesity Prescription Revenue Market Share by Application (2018-2034)
Figure 54. Europe Anti-Obesity Prescription Revenue Share by Country (2018-2034)
Figure 55. Europe Anti-Obesity Prescription Sales Quantity Share by Country (2018-2034)
Figure 56. Germany Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 57. France Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 58. U.K. Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 59. Italy Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 60. Russia Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 61. China Anti-Obesity Prescription Sales Quantity Market Share by Company in 2024
Figure 62. China Anti-Obesity Prescription Revenue Market Share by Company in 2024
Figure 63. China Anti-Obesity Prescription Sales Quantity Market Share by Type (2018-2034)
Figure 64. China Anti-Obesity Prescription Revenue Market Share by Type (2018-2034)
Figure 65. China Anti-Obesity Prescription Sales Quantity Market Share by Application (2018-2034)
Figure 66. China Anti-Obesity Prescription Revenue Market Share by Application (2018-2034)
Figure 67. APAC Anti-Obesity Prescription Sales Quantity Market Share by Company in 2024
Figure 68. APAC Anti-Obesity Prescription Revenue Market Share by Company in 2024
Figure 69. APAC Anti-Obesity Prescription Sales Quantity Market Share by Type (2018-2034)
Figure 70. APAC Anti-Obesity Prescription Revenue Market Share by Type (2018-2034)
Figure 71. APAC Anti-Obesity Prescription Sales Quantity Market Share by Application (2018-2034)
Figure 72. APAC Anti-Obesity Prescription Revenue Market Share by Application (2018-2034)
Figure 73. APAC Anti-Obesity Prescription Revenue Share by Region (2018-2034)
Figure 74. APAC Anti-Obesity Prescription Sales Quantity Share by Region (2018-2034)
Figure 75. Japan Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 76. South Korea Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 77. China Taiwan Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 78. Southeast Asia Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 79. India Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 80. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity Market Share by Company in 2024
Figure 81. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue Market Share by Company in 2024
Figure 82. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Anti-Obesity Prescription Sales Quantity Share by Country (2018-2034)
Figure 87. Middle East, Africa and Latin America Anti-Obesity Prescription Revenue Share by Country (2018-2034)
Figure 88. Brazil Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 89. Mexico Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 90. Turkey Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 91. Israel Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 92. GCC Countries Anti-Obesity Prescription Revenue (2018-2034) & (US$ Million)
Figure 93. Anti-Obesity Prescription Value Chain
Figure 94. Anti-Obesity Prescription Production Process
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed